Mehmet Asim Bilen, MD

Panelists discuss how integrating high-quality real-world evidence with clinical trial data enhances confidence in treatment decisions and guides tailored ARPI selection for patients with mCSPC.

Panelists discuss how understanding the generalizability of real-world evidence and clearly communicating its differences from trial data help clinicians personalize treatment and build patient trust.

Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences.

Panelists discuss how recognizing and mitigating common biases in real-world prostate cancer data helps clinicians interpret findings responsibly and apply them effectively in patient care.

Panelists discuss how prednisone coadministration with abiraterone impacts tolerability and monitoring in patients with cardiometabolic comorbidities, guiding safer, personalized treatment choices in mCSPC.

Panelists discuss how real-world evidence comparing apalutamide and abiraterone, including the impact of prednisone use, informs balanced and patient-specific first-line treatment choices.

Panelists discuss how biomarker and molecular testing inform long-term planning in mCSPC, guiding future therapeutic sequencing and improving precision in patient management.

Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.

Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.

Panelists discuss how advances in systemic therapy have reshaped the treatment landscape for mCSPC, enabling more individualized and proactive first-line care.

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.

"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.